LINCOLN PHARMACEUTICALS LTD.

Lincoln Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. All directors, senior management, promoters, and connected persons are advised not to trade during this period. The date for the Board of Directors' meeting to approve these financial results will be communicated separately.

Lincoln Pharmaceuticals Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The board also recommended a final dividend of ₹1.80 per equity share, representing 18% of the face value, for the financial year ended March 31, 2026. This dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting. For the year ended March 31, 2026, the company reported revenue from operations of ₹67,102.99 Lakhs and a net profit of ₹8,789.38 Lakhs.

Lincoln Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. For Q4 FY26, the company reported a standalone net profit of ₹11.63 crore on revenue from operations of ₹187.28 crore. For the full fiscal year FY26, standalone net profit stood at ₹87.89 crore, with revenue from operations reaching ₹671.03 crore. The Board of Directors also recommended a dividend of 18% (₹1.80 per share) for the year ended March 31, 2026, subject to approval at the upcoming Annual General Meeting.

Lincoln Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. For the full fiscal year 2026, the company reported Revenue from Operations of ₹67,102.99 Lakhs and a Net Profit of ₹8,789.38 Lakhs. The Basic Earnings Per Share (EPS) for FY26 stood at ₹43.88. The Board of Directors also recommended a dividend of 18% (₹1.80 per equity share of face value ₹10/-) for the year ended March 31, 2026, subject to approval by shareholders at the upcoming Annual General Meeting. The audit reports for the financial results were issued with an unmodified opinion.

Lincoln Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider the recommendation of a dividend on equity shares, if any. The trading window, which has been closed since April 1, 2026, will reopen 48 hours after the results are made public.

Lincoln Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider the recommendation of a dividend on equity shares, if any. The trading window has been closed from April 1, 2026, and will reopen 48 hours after the results are generally available.

Lincoln Pharmaceuticals Ltd has announced the closure of the trading window for dealing in the securities of the company. The closure will be in effect from April 01, 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and year ended March 31, 2026. The decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments thereto, and the Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the company. The date of the meeting of the Board of Directors to approve the Audited Financial Results will be informed in due course. Directors, Senior Management Personnel, Promoters, Promoter Group, and other Connected Persons are advised not to trade in securities of the company during the aforesaid period of closure.

Lincoln Pharmaceuticals Ltd. has announced its unaudited financial results for the quarter and nine months ended on 31st December 2025. The Board of Directors approved the standalone and consolidated financial results in their meeting held on 12th February 2026. The company's revenue from operations stands at 16,632.20 lakhs for the quarter and 48,375.26 lakhs for the nine months ended on 31st December 2025.

Lincoln Pharmaceuticals Ltd. held a Board Meeting on February 12, 2026, where they considered and approved the un-audited financial results for the quarter and nine months ended on December 31, 2025. The total income for the nine months ended on December 31, 2025, was 52,140.19 lakhs, with a profit before tax of 9,176.17 lakhs. The consolidated financial results include the results of the single business segment, Pharmaceutical Business, and the subsidiary, Zullinc Healthcare LLP. The auditor has carried out a limited review of the financial results.

Lincoln Pharmaceuticals Ltd has announced a board meeting scheduled for February 12, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and nine months ended on December 31, 2025. The meeting will be held at the company's registered office. In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for securities of the company has been closed from January 01, 2026, and will reopen after the expiry of 48 hours from the time the results become generally available.